In order to improve utilization of “data”, Ministry of Economy, Trade and Industry revised the Unfair Competition Prevention Act in May 2018. This revision provides remedies for misappropriation of “Protected Data” (effective date: July 1, 2019) and expands scope of protection related to Technological Restriction Measures, such as encryption (effective date: November 29, 2018).Source METI METI
Daikin Industries, Ltd. pledged non-assertion of HFC-32 patents, which have been filed after 2011.
Daikin looks to further facilitate the adoption of equipment using HFC-32 refrigerant.
The Fair Trade Commission has ordered baby goods maker Aprica Children’s Products G.K. to stop urging retailers to not sell its products below its proposed prices.Source The Japan Times
The JPO published a report of the current status of AI related applications in Japan and overseas.
According to the report, the number of applications related to AI technique has rapidly increased since 2014.
The number of applications in the US and China is outstanding.
Toyoda Gosei Co., Ltd. entered into a cross-licensing agreement on LED technique with Citizen electronics Co., Ltd.Source TOYOTA GOSEI (Japanese)
Five groups including JASRAC (Japanese Society for Rights of Authors) submitted three resolutions which were adopted at the CISAC General Agency to the Agency for Cultural Affairs. One of the resolutions is about private copy remuneration in Japan which urges the government of Japan “to expeditiously establish a new, functional, updated, modern and equitable private copying remuneration system”.Source JASRAC
Japan Fair Trade Commission published the result of an actual condition survey on exploitation of intellectual property and know-how of Japanese makers.
According to the survey, in 726 cases among about 16,000 answers, makers answered that their IP, know-how, client list, etc. had been exploited by big companies which had abused their superior conditions to the makers.
Japan Fair Trade Commission announced that it would take strict measures against such cases which violate the Act on Prohibition of Private Monopolization and Maintenance of Fair Trade or the Subcontract Act.
The Ground Panel has rendered a judgment.
This judgment clarifies the criteria for deciding the amount of damage
An English translation of the judgment will be soon published.
Nobel laureate demands higher cancer drug royalties than in their contract which was made in 2006.Source Nikkei Asian Review
The Japanese government is conferring with business leaders and lawyers to establish an international division within the Intellectual Property High Court where cases could be heard in English.Source Nikkei Asian Review
Chinese companies have surged ahead of their U.S. counterparts on a
Nikkei ranking of the top 50 patent filers for artificial intelligence
over the past three years, expanding their presence in the world’s most
prominent high-tech battleground.
Ministry of Economy, Trade and Industry uploaded an article on its homepage stating that “JPO announces that the Cabinet has approved the Bill for the Act of Partial Revision of the Patent Act. On March 1, 2019, the bill will be submitted to the ongoing 198th ordinary session of the Diet.” According to the article, the Partial Revision of the Patent Act includes “Creation of a new system under which neutral technological experts conduct on-site inspections of suspected infringers” and “Review of the method of calculating compensations for damages”.Source METI
A Japanese court handed down stiff penalties against three operators of a so-called leech site that facilitated piracy of copyrighted content.Source Nikkei Asian Review
The copyright term in Japan will be extended from 50 years to 70 years (effective on December 30).Source The Japan Times
Toray Industries, Inc., who possesses a patent covering an antipruritic agent “Nalfurafine”, sued generic companies, Sawai Pharmaceutical Co., Ltd. and Fuso Pharmaceutical Industries, Ltd., for patent infringement to the Tokyo District Court on December 13 to seek an injunction against the production, etc. of their products.
Because the patent relates to second medical use of known compounds and the term of the patent has been extended, one of the issues of this case is the scope of an extended patent right of a second medicinal use invention, on which issue no court decision has been made yet.Source Nikkei (Japanese)